Compare MDBH & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MDBH | FGEN |
|---|---|---|
| Founded | 1997 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.0M | 35.6M |
| IPO Year | 2023 | 2014 |
| Metric | MDBH | FGEN |
|---|---|---|
| Price | $3.43 | $8.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $146.50 |
| AVG Volume (30 Days) | 12.6K | ★ 41.5K |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.76 | ★ 53.38 |
| Revenue | $1,250,398.00 | ★ $8,298,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.42 | ★ $0.16 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.16 | $4.85 |
| 52 Week High | $7.98 | $21.94 |
| Indicator | MDBH | FGEN |
|---|---|---|
| Relative Strength Index (RSI) | 50.50 | 46.09 |
| Support Level | $3.17 | $8.30 |
| Resistance Level | $3.62 | $10.47 |
| Average True Range (ATR) | 0.17 | 0.58 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 57.78 | 15.85 |
MDB Capital Holdings LLC is an investment holding company that operates through its subsidiaries and focuses on early-stage technology companies through public offerings. The company's purpose is to engage with companies holding visionary technology, inventors, and technology entrepreneurs. The Company operates in two reportable segments: a broker dealer & intellectual property service, and the technology development segment. The broker dealer & intellectual property service segment, which derives key revenue, is engaged in conducting private and public securities offerings and offers in-depth patent research used for investment banking due diligence.
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.